Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837606 | 0.79 | HSP90AA1 (0.30) | HSP90AA1 | |
| SCHEMBL29145566 | 0.78 | — | — | |
| SCHEMBL10332553 | 0.77 | CA2 (0.35) | ALDH1A1MAPT | |
| SCHEMBL441113 | 0.75 | TSHR (0.45) | ALDH1A1MAPTFBP1MAPK1 | |
| SCHEMBL9320496 | 0.74 | CYSLTR2 (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL26325 | 0.72 | TSHR (0.48) | ALDH1A1HSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL10518198 | 0.72 | FBP1 (0.41) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL3044183 | 0.71 | ALDH1A1 (0.44) | MEN1ALDH1A1MAPTKMT2AFBP1 | |
| SCHEMBL2131010 | 0.71 | S100A4 (0.34) | MEN1ALDH1A1KMT2ATRPV1 | |
| SCHEMBL590426 | 0.71 | TDP1 (0.44) | MEN1ALDH1A1MAPTKMT2AFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0482771-B1 | Heterocyclic acids | ZENECA LTD (GB) | 1997-06-18 | — | — | EP | claimed |
| US-5219874-A | Heterocyclic acids | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-15 | — | — | US | claimed |
| EP-0482771-A2 | Heterocyclic acids | ZENECA LIMITED (GB) | 1992-04-29 | — | — | EP | claimed |
| EP-3339286-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-06-27 | — | — | EP | disclosed |
| EP-2427426-B1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-07 | — | — | EP | disclosed |
| US-9273149-B2 | Methods and compositions for determining the purity of chemically synthesized nucleic acids | VERI-Q, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140193855-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI-Q, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8697355-B2 | Methods and compositions for determining the purity of chemically synthesized nucleic acids | NORTH CAROLINA STATE UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| WO-2013092942-A1 | USE OF AMINOBENZAMIDE DERIVATIVES FOR CONTROLLING ANIMAL PARASITES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130071951-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | AGRIS PAUL F (US) | 2013-03-21 | — | — | US | disclosed |
| US-8323910-B2 | Methods and compositions for determining the purity of chemically synthesized nucleic acids | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20030044831-A1 | Antibody for use in the generation and protection of preferential nucleotide sequences | AGRIS PAUL F (US) | 2003-03-06 | — | — | US | disclosed |
| WO-2003003014-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI-Q, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-1242459-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | NORTH CAROLINA STATE UNIVERSITY (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020045167-A1 | Used for detecting incomplete deprotection of a synthetic oligonucleotide by immunoassay | VERI-Q, INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001049745-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | NORTH CAROLINA STATE UNIVERSITY (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0482771-B1 | Heterocyclic acids | ZENECA LTD (GB) | 1997-06-18 | — | — | EP | disclosed |
| US-5410064-A | Thromboxane A2 antagonists and inhibitors of thromboxane A2 synthase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-04-25 | — | — | US | disclosed |
| US-5219874-A | Heterocyclic acids | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-15 | — | — | US | disclosed |
| EP-0482771-A2 | Heterocyclic acids | ZENECA LIMITED (GB) | 1992-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140193855-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | RNGTT, NOP2, DCLRE1B | MEN1 3464/4885ALDH1A1 4333/4885MAPT 1505/4885 |
| US-20030044831-A1 | Antibody for use in the generation and protection of preferential nucleotide sequences | CD2BP2, IGSF11, RNGTT | MEN1 4224/4885ALDH1A1 4659/4885MAPT 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.